News

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after ...
BioSpace1h
Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III
After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...
Investing.com UK5h
Novo Nordisk falls as CagriSema obesity data shows no clear edge vs Zepbound
Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...
Stocks to Watch Monday: Tesla, Northern Trust, Fiserv, Novo Nordisk
Occidental Petroleum (OXY): Energy stocks gained modestly ...
pharmaphorum5h
ADA: Novo continues effort to rehabilitate CagriSema
Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...
STAT2d
Full data on Novo Nordisk’s new amylin drug raise dosing questions
Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...
24/7 Wall St.3d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (June 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
The Manila Times19h
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH ...
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety ...